Aequus Pharmaceuticals Inc (AQS.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14 | 35 | 39 | 50 | 25 |
| Receivables | 166 | 81 | 93 | 58 | 65 |
| Inventories | 5 | 97 | 157 | 38 | 99 |
| Other current assets | 0 | 0 | 0 | 0 | 45 |
| TOTAL | $196 | $236 | $304 | $282 | $307 |
| Non-Current Assets | |||||
| PPE Net | 0 | 0 | 0 | 518 | 551 |
| TOTAL | $0 | $0 | $0 | $518 | $551 |
| Total Assets | $196 | $236 | $304 | $800 | $858 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 6,029 | 6,029 | 6,029 | 6,029 | 5,927 |
| Accounts payable and accrued liabilities | 1,025 | 848 | 790 | 543 | 451 |
| Accrued Expenses | 36 | 24 | 42 | 100 | 88 |
| TOTAL | $7,090 | $7,084 | $6,990 | $6,796 | $6,587 |
| Non-Current Liabilities | |||||
| TOTAL | $0 | $425 | $425 | $459 | $491 |
| Total Liabilities | $7,090 | $7,508 | $7,415 | $7,255 | $7,078 |
| Shareholders' Equity | |||||
| Common Shares | 23,991 | 23,991 | 23,991 | 23,991 | 23,991 |
| Retained earnings | -35,300 | -35,671 | -35,507 | -34,862 | -34,644 |
| Other shareholders' equity | 4,416 | 4,408 | 4,406 | 4,416 | 4,433 |
| TOTAL | $-6,894 | $-7,272 | $-7,110 | $-6,455 | $-6,220 |
| Total Liabilities And Equity | $196 | $236 | $304 | $800 | $858 |